Rituximab versus cyclophosphamide for remission induction in active, severe antineutrophil cytoplasmic antibody-associated vasculitis: comment on the article by Chung et al

Arthritis Rheumatol. 2022 Mar;74(3):544-545. doi: 10.1002/art.42002. Epub 2022 Jan 18.

Authors

Siddharth Jain¹, G S R S N K Naidu¹, Aman Sharma¹

Affiliation

¹ Postgraduate Institute of Medical Education and Research, Chandigarh, India.

PMID: 34694068
DOI: 10.1002/art.42002

No abstract available

Publication types

Letter
Comment

MeSH terms

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis* / drug therapy
Antibodies, Antineutrophil Cytoplasmic*
Cyclophosphamide / therapeutic use
Humans
Remission Induction
Rituximab / therapeutic use

Substances

Antibodies, Antineutrophil Cytoplasmic
Rituximab
Cyclophosphamide